Search Result

Results for "

hepatic gene

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Acetyl-CoA Carboxylase (2) Acyltransferase (1) AMPK (1) Apoptosis (2) Asialoglycoprotein Receptor (ASGPR) (1) Collagen (1) FXR (3) Glutathione S-transferase (1) Glycolate Oxidase (1) Integrin (1) Interleukin Related (1) Isotope-Labeled Compounds (1) JAK (1) Keap1-Nrf2 (2) LXR (1) MMP (2) NF-κB (2) PPAR (3) Quinone Reductase (1) Reference Standards (2) REV-ERB (1) Small Interfering RNA (siRNA) (2) TGF-beta/Smad (2) TNF Receptor (1) VD/VDR (1) Wnt (1) β-catenin (1)
By Research Areas:	Cancer (1) Cardiovascular Disease (2) Endocrinology (1) Inflammation/Immunology (5) Metabolic Disease (14)
Oligonucleotides:	siRNA drugs (2) siRNAs (2)

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Natural
Products

Isotope-Labeled Compounds

Oligonucleotides

Targets Recommended: LAG-3 CGRP Receptor MALT1 Dan family RIG-I-like receptor (RLR) NEKs

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-132588

Lumasiran ALN-G01	Small Interfering RNA (siRNA) Glycolate Oxidase	Metabolic Disease
Lumasiran (ALN-G01), a siRNA product, reduces hepatic oxalate production by targeting glycolate oxidase. By silencing the gene encoding glycolate oxidase, Lumasiran depletes glycolate oxidase and thereby inhibits the synthesis of oxalate, which is the toxic metabolite that is directly associated with the clinical manifestations of Primary hyperoxaluria type 1 (PH1) .

HY-14414

GSK4112 10+ Cited Publications SR6452	REV-ERB Apoptosis	Metabolic Disease
GSK4112 (SR6452) is a Rev-erbα agonist with an EC₅₀ value of 0.4 μM. GSK4112 can be used as a chemical tool to probe the function of Rev-erbα in transcriptional repression, regulation of circadian biology, and metabolic pathways .

HY-N0468

Rebaudioside D 1 Publications Verification	FXR Acetyl-CoA Carboxylase	Metabolic Disease
Rebaudioside D is an orally active sweetener that targets and activates FXR, modulates Acetyl-CoA Carboxylase, and inhibits 3-hydroxy-3-methylglutaryl-CoA reductase. Rebaudioside D regulates bile acid homeostasis and lipid metabolism, reduces the synthesis rates of fatty acids and cholesterol, and exerts multiple effects including anti-adipogenesis, hepatoprotection, anti-steatosis, gut microbiota modulation, enhancement of secondary bile acid metabolism, anti-endotoxin activity, regulation of bile acid transport, and inhibition of bile acid efflux. Rebaudioside D also reduces body weight gain, visceral fat accumulation, hepatic triglyceride and cholesterol accumulation, hepatic lipid peroxidation, and decreases the circulating level of lipopolysaccharide-binding protein. Rebaudioside D additionally enhances the secondary bile acid metabolic pathway of intestinal bacteria, upregulates the gene expression of ileal organic solute transporter α, and downregulates the gene expression of hepatic bile salt export pump. Rebaudioside D does not affect glucose homeostasis, alter total caloric intake or fecal energy excretion, induce weight gain, exacerbate obesity, promote hepatic steatosis, impair brown adipose tissue function, nor change skeletal muscle metabolism-related proteins. Rebaudioside D can be used in diet-induced obesity and obesity-related research .

HY-47888

PLN-1474	Integrin	Inflammation/Immunology
PLN-1474 (compound 1) is an orally active and selective ανβ1 integrin inhibitor with an IC50 value of <50 nM. PLN-1474 reduces levels of pSMAD3/SMAD3 in liver, hepatic collagen gene expression and hepatic OHP concentration in liver fibrosis mouse model. PLN-1474 can be used for the research of preventing, delaying or researching a fibrotic or cirrhotic disease or disorder.

HY-156259

PF-07202954	Acyltransferase	Inflammation/Immunology
PF-07202954 is an orally active, highly selective DGAT2 inhibitor with an IC₅₀ of 10 nM against human DGAT2 and an IC₅₀ of 17 nM against rat DGAT2. PF-07202954 reduces triglyceride synthesis, decreases hepatic triglyceride content and plasma triglyceride levels, inhibits de novo lipogenesis, and suppresses the hepatic SREBP signaling pathway as well as the expression of SREBP target genes. PF-07202954 is applicable to research related to non-alcoholic steatohepatitis .

HY-139040

2-(Tetradecylthio)acetic acid	PPAR	Metabolic Disease
2-Tetradecylthio acetic acid is a pan-peroxisome proliferator activated receptor (pan-PPAR) activator. 2-Tetradecylthio acetic acid induces hypolipidemia. 2-Tetradecylthio acetic acid reduces plasma lipids and enhances hepatic fatty acid oxidation in rodents. 2-Tetradecylthio acetic acid increases the expression of genes involved in fatty acid uptake, activation, accumulation, and oxidation .

HY-141439

TBE 31	Keap1-Nrf2 Quinone Reductase Glutathione S-transferase Apoptosis TNF Receptor	Inflammation/Immunology Cancer
TBE 31 is an orally active Keap1/Nrf2 pathway activator and NQO1 inducer with a D_m value of 1.1 nM for NQO1. TBE 31 binds to cysteine residues of Keap1, inhibits ubiquitination and degradation of Nrf2, thereby activating the expression of ARE-dependent genes. TBE 31 induces cytoprotective enzymes including NQO1 and GST isoforms, promotes Nrf2 accumulation, and upregulates Nrf2-regulated genes related to antioxidation and lipid metabolism. TBE 31 inhibits pro-inflammatory responses, formation of AFB1-DNA adducts, endoplasmic reticulum stress, cell apoptosis (apoptosis), hepatic fibrosis, oxidative stress, and the expression of ChREBP. TBE 31 reduces the number of tumors in a mouse model of ultraviolet-induced skin carcinogenesis. TBE 31 enhances nerve growth factor-induced neurite outgrowth. TBE 31 attenuates LPS-induced serum TNF-α levels and immobility time in mice. TBE 31 can be used in research related to liver cancer, skin cancer, inflammation-related depression, and non-alcoholic steatohepatitis .

HY-145649A

Zilebesiran sodium AD-85481 sodium; ALN-AGT sodium	Small Interfering RNA (siRNA) Asialoglycoprotein Receptor (ASGPR)	Cardiovascular Disease
Zilebesiran (AD-85481; ALN-AGT) sodium is a long-acting liver-targeted small interfering RNA (siRNA) antihypertensive agent. Zilebesiran sodium binds to the hepatic asialoglycoprotein receptor (ASGPR), activates the RNA-induced silencing complex to degrade hepatic angiotensinogen mRNA, thereby inhibiting the gene expression and synthesis of angiotensinogen. Zilebesiran sodium dose-dependently reduces serum angiotensinogen levels and 24-hour ambulatory blood pressure, with its effect persisting throughout the circadian cycle. Zilebesiran sodium is applicable to research related to hypertension .

HY-N0468R

Rebaudioside D (Standard)	Reference Standards Acetyl-CoA Carboxylase FXR	Metabolic Disease
Rebaudioside D (Standard) is the analytical standard of Rebaudioside D. This product is intended for research and analytical applications. Rebaudioside D is an orally active sweetener that targets and activates FXR, modulates Acetyl-CoA Carboxylase, and inhibits 3-hydroxy-3-methylglutaryl-CoA reductase. Rebaudioside D regulates bile acid homeostasis and lipid metabolism, reduces the synthesis rates of fatty acids and cholesterol, and exerts multiple effects including anti-adipogenesis, hepatoprotection, anti-steatosis, gut microbiota modulation, enhancement of secondary bile acid metabolism, anti-endotoxin activity, regulation of bile acid transport, and inhibition of bile acid efflux. Rebaudioside D also reduces body weight gain, visceral fat accumulation, hepatic triglyceride and cholesterol accumulation, hepatic lipid peroxidation, and decreases the circulating level of lipopolysaccharide-binding protein. Rebaudioside D additionally enhances the secondary bile acid metabolic pathway of intestinal bacteria, upregulates the gene expression of ileal organic solute transporter α, and downregulates the gene expression of hepatic bile salt export pump. Rebaudioside D does not affect glucose homeostasis, alter total caloric intake or fecal energy excretion, induce weight gain, exacerbate obesity, promote hepatic steatosis, impair brown adipose tissue function, nor change skeletal muscle metabolism-related proteins. Rebaudioside D can be used in diet-induced obesity and obesity-related research .

HY-W001288

Indole-4-carboxaldehyde	NF-κB	Metabolic Disease
Indole-4-carboxaldehyde is an ergot alkaloid precursor. Indole-4-carboxaldehyde attenuates the methylglyoxal (MGO)-induced expression of inflammatory-related genes, such asTNF-α and IFN-γ by activating NF-κB without toxicity in HepG2 cells. Indole-4-carboxaldehyde reduces the MGO-induced AGE formation and the expression of the receptor for AGE (RAGE). Indole-4-carboxaldehyde can be used for the study of hepatic steatosis .

HY-178328

VDR agonist 4	VD/VDR Collagen TGF-beta/Smad MMP JAK	Metabolic Disease Inflammation/Immunology Endocrinology
VDR agonist 4 is an orally active potent VDR agonist. VDR agonist 4 exerts VDR-dependent antifibrotic activity by regulating multiple fibrosis-related genes to suppress α-SMA and collagen I production, thereby inhibiting hepatic stellate cell (HSC) activation. VDR agonist 4 improves CCl₄ (HY-RS16594)-induced hepatic fibrosis in mice. VDR agonist 4 can be used for liver fibrosis research .

HY-125129

Carlinoside	Keap1-Nrf2	Others
Carlinoside is a flavone glycoside with hepatoprotective efficiency. Carlinoside reduces hepatic bilirubin accumulation by stimulating bilirubin-UGT activity through Nrf2 gene expression. Carlinoside has the potential to intervene hyperbilirubinemia due to liver dysfunction .

HY-172105

Anti-NASH agent 2	PPAR	Metabolic Disease Inflammation/Immunology
Anti-NASH agent 2 (compound 21) is an inhibitor of de novo adipogenesis activity and α-SMA gene expression. Anti-NASH agent 2 improves hepatic steatosis, edema, inflammatory infiltrates, and liver fibrosis in NASH mouse models .

HY-133180

YW1128	Wnt β-catenin	Metabolic Disease
YW1128 (compound 3a) is a potent Wnt/β-Catenin inhibitor. YW1128 induces the proteasome degradation of β-catenin and subsequent inhibits the Wnt/β-catenin signaling in cells. YW1128 significantly decreases hepatic lipid accumulation. YW1128 improves glucose tolerance of high fat diet-fed mice without noticeable toxicity. YW1128 down regulates the genes involved in the glucose and fatty acid anabolism .

HY-139040R

2-(Tetradecylthio)acetic acid (Standard) Tetradecylthioacetic acid (Standard)	PPAR Reference Standards	Metabolic Disease
2-(Tetradecylthio)acetic acid (Standard) is the analytical standard of 2-(Tetradecylthio)acetic acid. This product is intended for research and analytical applications. 2-Tetradecylthio acetic acid is a pan-peroxisome proliferator activated receptor (pan-PPAR) activator. 2-Tetradecylthio acetic acid induces hypolipidemia. 2-Tetradecylthio acetic acid reduces plasma lipids and enhances hepatic fatty acid oxidation in rodents. 2-Tetradecylthio acetic acid increases the expression of genes involved in fatty acid uptake, activation, accumulation, and oxidation .

HY-185504

Nexiguran	Others	Others
Nexiguran is one component of Nexiguran ziclumeran and also an sgRNA targeting the human TTR gene. Nexiguran ziclumeran (NTLA-2001) is a CRISPR gene-editing therapy that targets hepatic TTR, and it can also be used for research on transthyretin amyloidosis .

HY-182795

Colchicine derivative-1	MMP Interleukin Related TGF-beta/Smad	Metabolic Disease
Colchicine derivative-1 is a colchicine derivative. Colchicine derivative-1 exhibits cytotoxicity against various cells. Colchicine derivative-1 arrests cancer cells at the G2/M phase of the cell cycle. Colchicine derivative-1 increases the levels of MMP-2, MMP-8, MMP-9, IL-2, IL-6, IL-17A, IL-22, IL-4, and IL-5 in the blood, inhibits the gene expression of hepatic fibrinogen α, β, γ and TGF-β1, and alleviates hepatic fibrosis symptoms in mice. Colchicine derivative-1 has antifibrotic activity and can be used in studies related to hepatic fibrosis .

HY-183279

FXR antagonist 4	FXR AMPK	Metabolic Disease
FXR antagonist 4 (Compound 4l) is an orally active, selective FXR antagonist with an IC₅₀ of 0.70 μM. FXR antagonist 4 binds to FXR, differentially regulates bile acid and lipid transporter genes, and exerts no effect on gluconeogenesis-related genes. FXR modulator 1 activates the AMPK signaling pathway to inhibit fatty acid synthesis. FXR modulator 1 alleviates hepatic steatosis, ballooning degeneration and fibrosis, and improves dyslipidemia. FXR modulator 1 can be used for research on metabolic dysfunction-associated steatohepatitis .

HY-182014

TLC-2716	LXR	Cardiovascular Disease Metabolic Disease
TLC-2716 is an orally available, gut- and liver-restricted inhibitor against LXRα and LXRβ, with EC₅₀ values of 7 nM and 15 nM, respectively. TLC-2716 represses LXRα/β transcriptional activity, downregulates genes involved in lipogenesis, lipid absorption and lipoprotein metabolism, and preserves peripheral reverse cholesterol transport. TLC-2716 reduces lipid accumulation, suppresses inflammation and fibrotic gene expression, enhances triglyceride-rich lipoprotein clearance, and improves glucose homeostasis and insulin sensitivity. TLC-2716 lowers serum and hepatic triglycerides, plasma cholesterol and other atherogenic lipid profiles in experimental models and humanized liver mice. TLC-2716 can be used for the research of dyslipidemia and related cardiometabolic disorders .

HY-W001288S

Indole-4-carboxaldehyde-13C	Isotope-Labeled Compounds NF-κB	Metabolic Disease
Indole-4-carboxaldehyde- ¹³C is the ¹³C-labeled Indole-4-carboxaldehyde (HY-W001288). Indole-4-carboxaldehyde is an ergot alkaloid precursor. Indole-4-carboxaldehyde attenuates the methylglyoxal (MGO)-induced expression of inflammatory-related genes, such asTNF-α and IFN-γ by activating NF-κB without toxicity in HepG2 cells. Indole-4-carboxaldehyde reduces the MGO-induced AGE formation and the expression of the receptor for AGE (RAGE). Indole-4-carboxaldehyde can be used for the study of hepatic steatosis .

Cat. No.	Product Name

HY-L101

Anti-Liver Cancer Compound Library	2,872 compounds
Liver cancer is one of the leading malignancies which occupies the second position in cancer deaths worldwide, becoming serious threat to human health. Hepatocellular carcinoma (HCC), also known as hepatoma is the most common type accounting for approximately 90% of all liver cancers. Current evidence indicates that during hepatocarcinogenesis, two main pathogenic mechanisms prevail: (1) cirrhosis associated with hepatic regeneration after tissue damage caused by hepatitis infection, toxins or metabolic influences, and (2) mutations occurring in single or multiple oncogenes or tumor suppressor genes. Both mechanisms have been linked with alterations in several important cellular signaling pathways. These include the RAF/MEK/ERK pathway, PI3K/AKT/mTOR pathway, WNT/b-catenin pathway, insulin-like growth factor pathway, c-MET/HGFR pathway , etc. MCE offers a unique collection of 2,872 compounds with identified and potential anti-liver cancer activity. MCE anti-liver cancer compound library is a useful tool for anti-liver cancer drugs screening and other related research.

Anti-Liver Cancer Compound Library

2,872 compounds

Liver cancer is one of the leading malignancies which occupies the second position in cancer deaths worldwide, becoming serious threat to human health. Hepatocellular carcinoma (HCC), also known as hepatoma is the most common type accounting for approximately 90% of all liver cancers.

Current evidence indicates that during hepatocarcinogenesis, two main pathogenic mechanisms prevail: (1) cirrhosis associated with hepatic regeneration after tissue damage caused by hepatitis infection, toxins or metabolic influences, and (2) mutations occurring in single or multiple oncogenes or tumor suppressor genes. Both mechanisms have been linked with alterations in several important cellular signaling pathways. These include the RAF/MEK/ERK pathway, PI3K/AKT/mTOR pathway, WNT/b-catenin pathway, insulin-like growth factor pathway, c-MET/HGFR pathway , etc.

MCE offers a unique collection of 2,872 compounds with identified and potential anti-liver cancer activity. MCE anti-liver cancer compound library is a useful tool for anti-liver cancer drugs screening and other related research.

Cat. No.	Product Name	Type

HY-W001288

Indole-4-carboxaldehyde	Biochemical Assay Reagents
Indole-4-carboxaldehyde is an ergot alkaloid precursor. Indole-4-carboxaldehyde attenuates the methylglyoxal (MGO)-induced expression of inflammatory-related genes, such asTNF-α and IFN-γ by activating NF-κB without toxicity in HepG2 cells. Indole-4-carboxaldehyde reduces the MGO-induced AGE formation and the expression of the receptor for AGE (RAGE). Indole-4-carboxaldehyde can be used for the study of hepatic steatosis .

Indole-4-carboxaldehyde

Biochemical Assay Reagents

Indole-4-carboxaldehyde is an ergot alkaloid precursor. Indole-4-carboxaldehyde attenuates the methylglyoxal (MGO)-induced expression of inflammatory-related genes, such asTNF-α and IFN-γ by activating NF-κB without toxicity in HepG2 cells. Indole-4-carboxaldehyde reduces the MGO-induced AGE formation and the expression of the receptor for AGE (RAGE). Indole-4-carboxaldehyde can be used for the study of hepatic steatosis .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0468

Rebaudioside D 1 Publications Verification	Structural Classification other families Classification of Application Fields Terpenoids Metabolic Disease Diterpenoids Plants Disease Research Fields Sweeteners Source Classification Food Research	FXR Acetyl-CoA Carboxylase
Rebaudioside D is an orally active sweetener that targets and activates FXR, modulates Acetyl-CoA Carboxylase, and inhibits 3-hydroxy-3-methylglutaryl-CoA reductase. Rebaudioside D regulates bile acid homeostasis and lipid metabolism, reduces the synthesis rates of fatty acids and cholesterol, and exerts multiple effects including anti-adipogenesis, hepatoprotection, anti-steatosis, gut microbiota modulation, enhancement of secondary bile acid metabolism, anti-endotoxin activity, regulation of bile acid transport, and inhibition of bile acid efflux. Rebaudioside D also reduces body weight gain, visceral fat accumulation, hepatic triglyceride and cholesterol accumulation, hepatic lipid peroxidation, and decreases the circulating level of lipopolysaccharide-binding protein. Rebaudioside D additionally enhances the secondary bile acid metabolic pathway of intestinal bacteria, upregulates the gene expression of ileal organic solute transporter α, and downregulates the gene expression of hepatic bile salt export pump. Rebaudioside D does not affect glucose homeostasis, alter total caloric intake or fecal energy excretion, induce weight gain, exacerbate obesity, promote hepatic steatosis, impair brown adipose tissue function, nor change skeletal muscle metabolism-related proteins. Rebaudioside D can be used in diet-induced obesity and obesity-related research .

HY-N0468R

Rebaudioside D (Standard)	Structural Classification other families Terpenoids Diterpenoids Plants Source Classification	Reference Standards Acetyl-CoA Carboxylase FXR
Rebaudioside D (Standard) is the analytical standard of Rebaudioside D. This product is intended for research and analytical applications. Rebaudioside D is an orally active sweetener that targets and activates FXR, modulates Acetyl-CoA Carboxylase, and inhibits 3-hydroxy-3-methylglutaryl-CoA reductase. Rebaudioside D regulates bile acid homeostasis and lipid metabolism, reduces the synthesis rates of fatty acids and cholesterol, and exerts multiple effects including anti-adipogenesis, hepatoprotection, anti-steatosis, gut microbiota modulation, enhancement of secondary bile acid metabolism, anti-endotoxin activity, regulation of bile acid transport, and inhibition of bile acid efflux. Rebaudioside D also reduces body weight gain, visceral fat accumulation, hepatic triglyceride and cholesterol accumulation, hepatic lipid peroxidation, and decreases the circulating level of lipopolysaccharide-binding protein. Rebaudioside D additionally enhances the secondary bile acid metabolic pathway of intestinal bacteria, upregulates the gene expression of ileal organic solute transporter α, and downregulates the gene expression of hepatic bile salt export pump. Rebaudioside D does not affect glucose homeostasis, alter total caloric intake or fecal energy excretion, induce weight gain, exacerbate obesity, promote hepatic steatosis, impair brown adipose tissue function, nor change skeletal muscle metabolism-related proteins. Rebaudioside D can be used in diet-induced obesity and obesity-related research .

HY-125129

Carlinoside	Flavonoids Classification of Application Fields Flavones Cymbopogon citratus Gramineae Other Diseases Phenols Polyphenols Plants Disease Research Fields Source Classification	Keap1-Nrf2
Carlinoside is a flavone glycoside with hepatoprotective efficiency. Carlinoside reduces hepatic bilirubin accumulation by stimulating bilirubin-UGT activity through Nrf2 gene expression. Carlinoside has the potential to intervene hyperbilirubinemia due to liver dysfunction .

Cat. No.	Product Name	Chemical Structure

HY-W001288S

Indole-4-carboxaldehyde-13C
Indole-4-carboxaldehyde- ¹³C is the ¹³C-labeled Indole-4-carboxaldehyde (HY-W001288). Indole-4-carboxaldehyde is an ergot alkaloid precursor. Indole-4-carboxaldehyde attenuates the methylglyoxal (MGO)-induced expression of inflammatory-related genes, such asTNF-α and IFN-γ by activating NF-κB without toxicity in HepG2 cells. Indole-4-carboxaldehyde reduces the MGO-induced AGE formation and the expression of the receptor for AGE (RAGE). Indole-4-carboxaldehyde can be used for the study of hepatic steatosis .

Indole-4-carboxaldehyde-13C

Indole-4-carboxaldehyde- ¹³C is the ¹³C-labeled Indole-4-carboxaldehyde (HY-W001288). Indole-4-carboxaldehyde is an ergot alkaloid precursor. Indole-4-carboxaldehyde attenuates the methylglyoxal (MGO)-induced expression of inflammatory-related genes, such asTNF-α and IFN-γ by activating NF-κB without toxicity in HepG2 cells. Indole-4-carboxaldehyde reduces the MGO-induced AGE formation and the expression of the receptor for AGE (RAGE). Indole-4-carboxaldehyde can be used for the study of hepatic steatosis .

Cat. No.	Product Name		Classification

HY-132588

Lumasiran ALN-G01		siRNAs siRNA drugs
Lumasiran (ALN-G01), a siRNA product, reduces hepatic oxalate production by targeting glycolate oxidase. By silencing the gene encoding glycolate oxidase, Lumasiran depletes glycolate oxidase and thereby inhibits the synthesis of oxalate, which is the toxic metabolite that is directly associated with the clinical manifestations of Primary hyperoxaluria type 1 (PH1) .

HY-145649A

Zilebesiran sodium AD-85481 sodium; ALN-AGT sodium		siRNAs siRNA drugs
Zilebesiran (AD-85481; ALN-AGT) sodium is a long-acting liver-targeted small interfering RNA (siRNA) antihypertensive agent. Zilebesiran sodium binds to the hepatic asialoglycoprotein receptor (ASGPR), activates the RNA-induced silencing complex to degrade hepatic angiotensinogen mRNA, thereby inhibiting the gene expression and synthesis of angiotensinogen. Zilebesiran sodium dose-dependently reduces serum angiotensinogen levels and 24-hour ambulatory blood pressure, with its effect persisting throughout the circadian cycle. Zilebesiran sodium is applicable to research related to hypertension .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.

hepatic gene

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

NaturalProducts

Isotope-Labeled Compounds

Oligonucleotides

Natural
Products